Development of a Mucosal Permeable Drug Carrier for the Nose to Brain Pathway to Target Brain Diseases

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20725
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0801:Pharmaceutical sciences and related fields
• Research Institution: Showa Pharmaceutical University
• Principal Investigator: Hagiwara Fumiko 昭和薬科大学, 薬学部, 特任助教 (00963993)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: DDS / Nose-to-Brain / アデノウイルス / CAR / BBB

Outline of Final Research Achievements

To create a mutant Ad protein capable of acting in mice using a phage display library method, the hCAR-binding region of human Ad was first incorporated into a phage plasmid as the target gene, and phage particles were generated. The specific binding of the recombinant phage particles to hCAR-expressing cells was evaluated by flow cytometry, and no difference was observed between the wild-type and recombinant phage particles. This indicates that the target protein may not be presented on the phage, or may be presented but unable to bind to CAR in the phage-bound state.

Free Research Field

DDS

Academic Significance and Societal Importance of the Research Achievements

今後、ファージディスプレイ法を用いてマウスに作用可能な変異型Adタンパク質の創製に向けて、ファージに結合した状態の目的タンパク質をCARへ結合させるため、新たにプラスミドを設計しなおす予定である。Adタンパク質キャリアの慢性脳疾患への応用の可能性を検討するために、疾患モデルマウスを用いた治療実験は不可欠であることから、本研究での変異型Adタンパク質の創製には意義があると考える。Adタンパク質キャリアの治療用キャリアとしての有用性を検討することで、DDS研究への貢献につながると考えられる。